Questions
  • Please use the Q&A panel to submit your questions
  • Send questions to “All Panelist”

Fabulous Prizes
Agenda

• Overview
  – Esophagus
  – Stomach
• Quiz 1
• Break
• CSv2
  – Esophagus
  – Stomach
• Quiz 2
• Treatment
  – Esophagus
  – Stomach
• Review of Exercises

Overview

Epidemiology-Esophagus

• Estimated new cases and deaths from esophageal cancer in the United States in 2009:
  – New cases: 16,470
  – Deaths: 14,530
• The incidence of esophageal cancer has risen in recent decades, with a shift in histologic type and primary tumor location.
Epidemiology-Esophagus

- Fewer than 50% of esophageal cancers are squamous cell carcinomas.
- Adenocarcinomas, typically arising in Barrett esophagus, account for at least 50% of malignant lesions, and the incidence of this histology appears to be rising.

Histology

- Squamous Cell Carcinoma
  - Typically found in the upper two thirds of the esophagus.
- Adenocarcinoma
  - Usually forms in the lower third of the esophagus, near the stomach.

Barrett’s Esophagus

- Repeated exposure to acidic stomach contents washing back (refluxing) through the lower esophageal sphincter may cause squamous cells to be replaced by glandular cells resembling those cells in the stomach.
High Grade Dysplasia

• The terminology preferred by pathologists for carcinoma in situ of the esophagus is high grade dysplasia.
• This terminology is not reportable to most cancer registries.
  – Therefore, it may be a future issue that early/very low stage esophageal cancer is under-reported as a result of registry reporting terminology.
• If high grade dysplasia of the esophagus is a reportable cancer, it should be coded as 00 in CS Extension.

CS Manual Section I Part 2 Page 29 Version 02.00.01

Question

• The esophagus chapter in AJCC 7 specifically redefined the explanation of Tis (for the esophagus) to high grade dysplasia (formally called in situ). Since it seems to be universal that pathologists will no longer use in situ when describing tissue in the esophagus, will high grade dysplasia of the esophagus be reportable?

Answer

• AJCC staging does not determine reportability. This is up to the standard setters, state and federal law. Please discuss with your facility’s cancer committee regarding whether this should be reportable-by-agreement for your facility.

(I & R Team)
47292
4/8/2010
ICD-O-3 Topography

Based on Landmarks
- Cervical esophagus (C15.0)
- Thoracic esophagus (C15.1)
  - Upper Thoracic
  - Mid Thoracic
- Abdominal esophagus (C15.2)
  - Lower Thoracic

Based on Measurement
- Upper 1/3 esophagus (C15.3)
- Proximal third of esophagus
- Middle 1/3 esophagus (C15.4)
- Mid third of esophagus
- Lower 1/3 esophagus (C15.5)
- Distal esophagus
**Esophagogastric junction (EGJ)**

- Esophagogastric junction
  - Cardia
  - Gastroesophageal junction

- The opening or junction between the esophagus and the stomach, and it is between 0.1 and 0.4 cm in length.

---

**Esophagogastric junction (EGJ)**

- The cardia/EGJ, and the proximal 5cm of the fundus and body of the stomach have been moved from the Stomach schema and added to Esophagus effective with AJCC TNM 7th Edition.

---

**Esophagogastric junction (EGJ)**

- If the midpoint of the tumor is within 5 cm below the cardia and the lesion extends to or across the cardia, the case should be coded with the EsophagusGEJunction schema.
**Esophagogastric junction (EGJ)**

- If the midpoint of the tumor is within 5 cm below the cardia and the lesion does not extend to the cardia, the case should be coded with the stomach schema.

**Esophagogastric junction (EGJ)**

- Any tumor with a midpoint more distal than 5 cm from the cardia is coded with the stomach schema.

**Layers of the Esophageal Wall**

- **Mucosa**
  - Surface epithelium, lamina propria, and muscularis mucosa
- **Submucosa**
  - Connective tissue, blood vessels, and glands
- **Muscularis (middle layer)**
  - Striated and Smooth Muscle
- **Adventitia**
  - Connective tissue that merges with connective tissue of surrounding structures
- **No Serosa**
Multiple Primary/Histology Rules

- Other Rules
  - Esophagus, EGI, Stomach
- Rule M11
  - Tumors with ICD-0-3 topography codes that are different at the second (Cxxx) and/or third characters (Cxxx) are multiple primaries.
    - Tumor in the cervical esophagus (C15.0) and another in the EGI (C16.0) are multiple primaries.

Multiple Primary/Histology Rules

- Rule H16
  - Code the appropriate combination/mixed code (Table 2) when there are multiple specific histologies or when there is a non-specific histology with multiple specific histologies
    - Pathology shows a 3 cm squamous cell carcinoma with a small adenocarcinoma component.
    - Per table 2 code as adenosquamous carcinoma 8560/3.

Question

- Primary site question: A patient had a ruptured esophagus 25 years ago and had a segment of colon removed and transplanted to serve as esophagus.
- In 2007, the patient was diagnosed with carcinoma in a polyp by endoscopic biopsy of the transplanted 'esophagus'.
- What is the primary site code? Is this the same site schema to be used for collaborative staging and surgery coding?
Answer

- Code the primary site esophagus, NOS (C15.9). Use the surgery codes and collaborative staging schema for esophagus. Document the unusual nature of this case in text fields. See also SINQ 20021078.
  - SINQ 20091017
  - Last updated 4/13/2009

Grade

- For Esophagus and EGJ, grade is required to derive AJCC TNM stages 0-IIA
- Standard four grade grading system
  - Well differentiated
  - Moderately differentiated
  - Poorly differentiated
  - Undifferentiated

Grade

- C T1a N0 M0 G1 Stage IA
  - Treatment options include
    - Esophagectomy
    - Endoscopic mucosal resection
    - Other ablative technique
- C T1a N0 M0 G2-3 Stage IB
  - Esophagectomy
Upper GI Diagnostic Tests

Imaging
- Upper GI Series (Barium Swallow)
- Computed tomography (CT or CAT) scan
- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET) scan
  - PET-CT
  - FDG-PET

Endoscopy
- Esophagogastroduodenoscopy (EGD)
- Endoscopic Ultrasound (EUS)
**Overview**

**Stomach**

---

**Stomach: Epidemiology**

- 2009 estimates in the United States
  - New cases: 21,130
  - Deaths: 10,620
- Environmental risk factors
  - *Helicobacter pylori* (H. pylori) infection
  - Smoking
  - High salt intake

---

**Stomach: Epidemiology**

- Adenocarcinoma is histology in 90-95% of stomach malignancies
- Cancer originating in distal stomach has decreased in United States since the 1930’s
- Cancer originating in cardia or esophagogastric junction has rapidly increased during last 2 decades
Anatomy of the Stomach

Layers of the Stomach Wall

Image source: SEER Training Website
Regional Lymph Nodes of the Stomach

- Left gastric
- Pancreaticosplenic
- Pancreatoduodenal
- Perigastric, NOS
- Peripancreatic
- Right gastric
- Splenic
- Superior mesenteric
- Celiac
- Hepatic
- Hepatoduodenal (for lesser curvature only)

Stomach: Common Metastatic Sites

- Liver
- Peritoneal surfaces
  - Malignant peritoneal cytology is classified as metastatic disease
- Distant lymph nodes
  - Retropancreatic
  - Para-aortic
  - Portal
  - Retroperitoneal
  - Mesenteric

Prognostic Factors for Stomach Cancer

- Treatment
  - Patients not resected have poor prognosis
- Depth of invasion into the wall of the stomach
- Regional lymphatic spread
- Tumor location
  - Proximal lesions have less favorable prognosis than distal lesions
- Serum levels for CEA and CA 19-9
Rx Hosp – Surg App 2010
Approach – Surgery of Primary Site at this Facility

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No surgical procedure of primary site at this facility</td>
</tr>
<tr>
<td>1</td>
<td>Robotic assisted</td>
</tr>
<tr>
<td>2</td>
<td>Robotic converted to open</td>
</tr>
<tr>
<td>3</td>
<td>Endoscopic</td>
</tr>
<tr>
<td>4</td>
<td>Endoscopic converted to open</td>
</tr>
<tr>
<td>5</td>
<td>Open or approach unspecified</td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether surgery performed at this facility</td>
</tr>
</tbody>
</table>

CSv2

Esophagus
Esophagogastric junction
Stomach

Esophagus
C15.0 Cervical esophagus
C15.1 Thoracic esophagus
C15.2 Abdominal esophagus
C15.3 Upper third of esophagus
C15.4 Middle third of esophagus
C15.5 Lower third of esophagus
C15.8 Overlapping lesion of esophagus
C15.9 Esophagus, NOS
Tumor Size

- For esophagus, this field is used for size of tumor/length of involved esophagus

Question

- For CS Tumor Size, the note says, "For esophagus, this field is used for size/length of involved esophagus."
- Define the length of involved tumor and how is this determined?

Answer

- This is the longest dimension of the tumor or the measurement of the esophagus that has cancer in it, such as the tumor involved the esophagus from 18cm to 26cm, which would mean it was an 8cm tumor.
- It can be found on the pathology report for a resected tumor, and if the information is not available then it would be taken from imaging or other reports according to the priority order in Part I of the CS Manual.
  - (I & R Team) 24240
**CS Extension**

- Identifies the contiguous growth of the primary tumor within the esophagus or its direct extension into neighboring organs and/or tissues.

**Adjacent Structures**

**T4a**
- Pleura-peritoneum
- Pericardium
- Diaphragm

**T4b**
- Aorta
- Carotid vessels
- Azygos vein
- Trachea
- Left main bronchus
- Vertebral body

**CS Lymph nodes**

- In 7th Edition, regional lymph nodes for any part of esophagus fall in the range from peri-esophageal/cervical to celiac region.
- Lymph nodes from the supraclavicular region down to the celiac region previously considered to be distant are now regional.
Regional Nodes Positive

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>All nodes examined are negative</td>
</tr>
<tr>
<td>01-89</td>
<td>1 to 89 nodes are positive</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes are positive</td>
</tr>
<tr>
<td>95</td>
<td>Positive aspiration or core biopsy of lymph node(s) was performed</td>
</tr>
<tr>
<td>97</td>
<td>Positive nodes are documented, but the number is unspecified</td>
</tr>
<tr>
<td>98</td>
<td>No nodes were examined</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reg LN Pos: Instructions for Coding

- Count in Reg LN Pos only lymph nodes with micrometastases or larger
  - Metastases greater than 0.2 mm in size
- Count in Reg LN Pos metastases in lymph nodes with no size of metastases stated
- Do not count in Reg LN Pos isolated tumor cells (ITC) found in regional lymph nodes
- **Exception:** Count nodes with positive ITC for cutaneous melanoma and Merkel cell carcinoma in Reg LN Pos

Regional Nodes Examined

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No nodes were examined</td>
</tr>
<tr>
<td>01-89</td>
<td>1 to 89 nodes were examined</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes were examined</td>
</tr>
<tr>
<td>95</td>
<td>No regional nodes were removed, but aspiration or core biopsy of regional nodes was performed</td>
</tr>
<tr>
<td>96</td>
<td>Regional lymph node removal was documented as a sampling, and the number of nodes is unknown/not stated</td>
</tr>
<tr>
<td>97</td>
<td>Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated</td>
</tr>
<tr>
<td>98</td>
<td>Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Reg LN Pos/Reg LN Exam
Instructions for Coding

• Priority of lymph node counts
  – Final diagnosis
  – Synoptic report
  – Microscopic
  – Gross

Aspiration/Core Biopsy

• Use code 95 for Reg Nodes Pos and Reg Nodes Ex when a positive lymph node is aspirated and there are no surgically resected lymph nodes.

Cervical Esophagus primary

• 5/21/10-FNA biopsy of an enlarged cervical lymph node was positive for carcinoma. No further surgical procedures.
  – Regional Nodes Pos 95
  – Regional Nodes Ex 95

Aspiration/Core Biopsy

• Use code 95 for Reg Nodes Pos when a positive lymph node is aspirated and any surgically resected lymph nodes are negative.

Cervical Esophagus primary

• 5/21/10-FNA biopsy of an enlarged cervical lymph node was positive for carcinoma.
• 5/30/10-Partial esophagectomy w/ cervical lymph node dissection. 00/10 lymph nodes positive.
  – Reg Nodes Pos 95
  – Reg Nodes Ex 10
Aspiration/Core Biopsy

- **Do not count** a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Examined.

Cervical Esophagus primary
- 5/21/10-FNA biopsy of an enlarged cervical lymph node was positive for carcinoma.
- 5/30/10-Partial esophagectomy w/ cervical lymph node dissection. 03/10 lymph nodes positive.
  - Reg Nodes Pos 03
  - Reg Nodes Ex 10

---

Aspiration/Core Biopsy

- If the positive aspiration or core biopsy is from a node in a different node region, **include** the node in the count of Reg LN Pos and Reg LN Exam.

Cervical Esophagus primary
- 5/21/10-FNA biopsy of an enlarged mediastinal lymph node was positive for carcinoma.
- 5/30/10-Partial esophagectomy w/ cervical lymph node dissection. 03/10 lymph nodes positive.
  - Reg Nodes Pos 04
  - Reg Nodes Ex 11

---

Aspiration/Core Biopsy

- If the location of the lymph node that is aspirated or core-biopsied is not known, assume it is part of the lymph node chain surgically removed, and **do not include** it in the count of Reg LN Pos and Reg LN Exam.

Cervical Esophagus primary
- 5/21/10-FNA biopsy of an enlarged lymph node was positive for carcinoma.
- 5/30/10-Partial esophagectomy w/ cervical lymph node dissection. 03/10 lymph nodes positive.
  - Reg Nodes Pos 03
  - Reg Nodes Ex 10
CS Mets

- Sites of distant mets may include
  - Non regional lymph nodes
  - Brain
  - Lung
  - Liver
  - Bone

Site Specific Factors

Required by CoC and SEER

- Site Specific Factor 1
  - Clinical Assessment of Regional Lymph Nodes

Site Specific Factors

Not Required by CoC and SEER

- Site Specific Factor 2
  - Specific Location of Tumor
- Site Specific Factor 3
  - Number of Regional Lymph Nodes with Extracapsular tumor
- Site Specific Factor 4
  - Distance to proximal edge of tumor from incisors
- Site Specific Factor 5
  - Distance to distal edge of tumor from incisors
Esophagogastric Junction

C16.0 Cardia, Esophagogastric junction (EGJ)
C16.1 Fundus of stomach, proximal 5cm only
C16.2 Body of stomach, proximal 5cm only

Esophagogastric junction (EGJ)

- If the midpoint of the tumor is within 5 cm below the cardia and the lesion extends to or across the cardia, the case should be coded with the EsophagusGEJunction schema.

Esophagogastric junction (EGJ)

- Tumor Size
  - Standard
- CS Ext
  - Similar to esophagus schema
- CS Lymph Nodes
  - List of nodes different from esophagus schema
- CS Mets
  - Similar to esophagus schema
Site Specific Factors

- Site Specific Factor 1 (Required by CoC and SEER)
  - Clinical Assessment of Regional Lymph Nodes
- Specific Factor 2 = 988
- Site-Specific Factor 3
  - Number of Regional Lymph Nodes with Extracapsular tumor
- CS Site-Specific Factor 4
  - Distance to proximal edge of tumor from incisors
- CS Site-Specific Factor 5
  - Distance to distal edge of tumor from incisors

Site Specific Factors

- Site Specific Factor 25 (Required by CoC and SEER)
  - Involvement of Cardia and Distance from Esophagogastric Junction (EGJ)
  - Schema Discriminator
  - If the primary site code is stomach and involvement of EGJ and distance from EGJ is unknown but a physician stages the case using esophagus definitions, assign to code 060. Collaborative Stage will use the EsophagusGEJunction schema to assign TNM and AJCC stage.

Adenocarcinoma/Squamous Cell Carcinoma

- Effective with AJCC TNM 7th Edition, there are separate stage groupings for squamous cell carcinoma and adenocarcinoma.
  - Since squamous cell carcinoma typically has a poorer prognosis than adenocarcinoma, a tumor of mixed histopathologic type or a type that is not otherwise specified should be classified as squamous cell carcinoma.
- Applies to both Esophagus and EGJ schema
**Stomach**

C16.1 Fundus of stomach  
C16.2 Body of stomach  
C16.3 Gastric antrum  
C16.4 Pylorus  
C16.5 Lesser curvature of stomach, NOS  
C16.6 Greater curvature of stomach, NOS  
C16.8 Overlapping lesion of stomach  
C16.9 Stomach, NOS

---

**CS Extension: Stomach**

- Identifies the contiguous growth of the primary gastric tumor within the stomach or its direct extension into neighboring organs and/or tissues  
- Staging of primary gastric adenocarcinoma is dependent on depth of penetration of the primary tumor

---

**CS Lymph Nodes: Stomach**

- Identifies the regional nodes of the stomach involved with cancer at the time of diagnosis  
- Modified N categories for the stomach in AJCC 7th Ed.  
  - N1: Metastasis in 1-2 regional lymph nodes  
  - N2: Metastasis in 3-6 regional lymph nodes  
  - N3: Metastasis in 7 or more regional lymph nodes  
    - N3a: Metastasis in 7-15 regional lymph nodes  
    - N3b: Metastasis in 16 or more regional lymph nodes
Collecting Cancer Data: Esophagus and Stomach

CS Lymph Nodes Eval: Stomach

- Used primarily to derive staging basis for N category
- Records how CS Lymph Nodes code was determined based on diagnostic methods used and their intent
- Designates N category as clinical or pathologic based on intent
  - Staging basis is clinical when intent is workup
  - Staging basis is pathologic when intent is treatment

CS Lymph Nodes Eval: Stomach

- Microscopic assessment of regional nodes that is part of workup to choose treatment plan is clinical staging
  - T category is clinical
- Microscopic assessment of regional nodes that is part of treatment is pathologic staging
  - T category is pathologic

CS Lymph Nodes Eval: Stomach

- Microscopic assessment of highest N category is always pathologic
- If lymph node dissection is not performed after neoadjuvant treatment, use code 0 or 1
- Only codes 5 and 6 are used if node assessment is performed after neoadjuvant therapy
Collecting Cancer Data: Esophagus and Stomach

CS Lymph Nodes Eval: Stomach

- Example: Patient had endoscopic paratracheal node biopsy because of hard lump in low neck. Biopsy confirmed metastatic lung cancer. Treatment was chemoradiation.
  - What is the code for CS Lymph Nodes Eval?
    - 1

CS Lymph Nodes Eval: Stomach

- Example: Endoscopic ultrasound identified small lesion of the fundus; no lymphadenopathy identified; biopsy documented adenocarcinoma. Patient had subtotal upper gastrectomy; 1.5 cm adenocarcinoma of the stomach; 0/16 perigastric nodes positive.
  - What is the code for CS Lymph Nodes Eval?
    - 3

CS Lymph Nodes Eval: Stomach

- Example: Endoscopic ultrasound showed malignant lesion of the lesser curvature of the stomach invading the muscularis propria with malignant lesser curvature nodes, clinically N1. Patient received pre-operative chemotherapy followed by partial gastrectomy. Gastrectomy path showed 1 cm lesser curvature lesion, adenocarcinoma, confined to mucosa; 22 regional nodes negative.
  - What is the code for CS Lymph Nodes Eval?
    - 5
CS Mets at DX: Stomach

- Identifies involved distant metastatic sites at time of diagnosis
- Classifies involvement of some intra-abdominal lymph nodes as distant metastasis
  - Retropancreatic
  - Para-aortic
  - Portal
  - Retroperitoneal
  - Mesenteric

CS SSF1: Stomach

Clinical Assessment of Regional Lymph Nodes

- Documents clinical assessment of regional lymph nodes prior to treatment
- Code as follows if clinically positive nodes stated but clinical N category not stated
  - 100: Metastasis in 1-2 regional lymph nodes (N1)
  - 200: Metastasis in 3-6 regional lymph nodes (N2)
  - 300: Metastasis in 7 or more regional lymph nodes (N3)
    - 310: Metastasis in 7-15 regional lymph nodes (N3a)
    - 320: Metastasis in 16 or more regional lymph nodes (N3b)

CS SSF2: Stomach

Specific Location of Tumor

- Identifies specific location of the tumor within the stomach
SSF13: Stomach
Carcinoembryonic Antigen (CEA)
• Code the interpretation of highest lab value of CEA prior to treatment

CS SSF14: Stomach
Carcinoembryonic Antigen (CEA) Lab Value
• Record in nanograms/milliliter highest CEA lab value prior to treatment

CS SSF15: Stomach
CA 19-9 Lab Value
• Record in units/milliliter the highest CA 19-9 lab value prior to treatment
CS SSF25: Stomach
Involvement of Cardia & Distance from EGJ

- Fundus (C16.1) and body (C16.2) of stomach can be assigned to either EsophagusGEJunction or Stomach CSv2 schema
- SSF25 is schema discriminator field needed for CS algorithm to determine which schema to select when site is C16.1 or C16.2

Treatment

NCCN Guidelines
Surgery

• Endoscopic Mucosal Resection
  – A small cap is fitted on the end of the endoscope that has a small wire loop.
  – The nodule is suctioned into the cap and the wire loop is closed while cautery is applied.
  – Code as 27
• This may be followed by photodynamic therapy.
  – Code 21

Surgery

• Esophagectomy
  – Removal of a section of the esophagus.
  – Esophagus is reconstructed using another organ such as the stomach or large intestine.
  – Code 30
• Esophagogastrectomy
  – Removal of a section of the esophagus and the fundus of the stomach.
  – Stomach is surgically attached to the remaining esophagus.
  – Code 53
• En bloc lymph node dissection

Chemo/Radiation

• Preoperative chemotherapy or preoperative chemoradiation is common among patients with localized surgically resectable disease.
  – 5-FU and cisplatin
  – 50 Gy at Gy/d
• For advanced disease squamous cell carcinoma seems to be more sensitive to chemotherapy, chemoradiation and RT. However, the long term outcome is the same.
Treatment by Stage

- Tumors involving mucosa, but not invading submucosa (T1a)
  - Esophagectomy, EMR or other ablative technique
- Tumor invades into, but not through the submucosa (T1b)
  - Medically fit, potentially resectable
    - Esophagectomy

- Medically fit patients with resectable locoregional disease (T1b N1, T2-T4 NX-N0-N1, or stage 4a)
  - Preoperative chemotherapy
    - Adenocarcinoma of the distal esophagus or EGJ
  - Preoperative chemoradiation
  - Definitive chemoradiation
- Distant (T4b or M1)
  - Chemotherapy
  - Palliative measures

Surgical Outcome

- No cancer at resection margins
  - Node negative squamous cell carcinoma
    - Observe
  - Node negative Adenocarcinoma
    - Tis, T1a or T1b
      - Observe
    - T2
      - Observe or chemoradiation
    - T3
      - Chemoradiation
**Surgical Outcome**

- No cancer at resection margins
  - Node positive squamous cell carcinoma
    - Observe
  - Node positive adenocarcinoma in the proximal or mid esophagus
    - Observe or Chemoradiation
  - Node positive adenocarcinoma of the distal esophagus or EGJ
    - Chemoradiation or palliative therapy

**Surgical Outcome**

- Positive resection margins
  - R1-Microscopic residual cancer
    - Chemoradiation
  - R2-Macroscopic residual cancer
    - Chemoradiation or palliative therapy

**Treatment by Stage**

- Medically unfit or surgery not elected or unresectable tumor; patient able to tolerate chemotherapy
  - Concurrent radiation and chemotherapy
  - Chemotherapy alone
  - Radiation alone
  - Best supportive care
Treatment by Stage

- Medically unfit or surgery and patient unable to tolerate chemotherapy
  - Palliative radiation therapy

Question

- If a patient with a diagnosis of distal esophagus cancer and liver mets had dysphagia to solid foods and the physician placed a jejunostomy tube, is the tube considered palliative treatment?

Answer

- Updated in I&R January, 2010 - A gastrostomy tube (also called a G-tube) is a tube that's inserted through the skin and the stomach wall, directly into the stomach.
- It is given for a purpose to provide nutrition for the patients who have difficulty swallowing or are unable to intake enough nutrition by mouth, but it does not help the patient to relieve dysphasia or esophageal obstruction, and should not be coded.
  - (I & R Team) 22886
Stomach

Treatment by Stage

- Tumors involving mucosa but not invading submucosa
  - Endoscopic mucosal resection (EMR) or surgery
- Locoregional tumors
  - Medically fit, potentially resectable
    - Surgery
    - Preoperative chemotherapy followed by surgery
    - Preoperative chemoradiation followed by surgery
    - Postoperative treatment depends on surgical outcome

Treatment by Stage

- Locoregional tumors
  - Medically fit, unresectable
    - Radiation therapy + concurrent 5-FU radiosensitization
    - Chemotherapy
  - Medically unfit
    - Radiation therapy + concurrent 5-FU radiosensitization
    - Palliative care
- Distant metastasis
  - Palliative care
Surgical Outcome

- No cancer at resection margins
  - Tis or T1 N0
  - Observe
- T2 N0
- Observe
  - Chemoradiation
  - T3, T4, or any T and N+
  - Radiation therapy + 5FU radiosensitization + chemotherapy

Surgical Outcome

- Microscopic residual cancer
  - Radiation therapy + 5FU radiosensitization + chemotherapy
- Macroscopic residual cancer
  - Radiation therapy + 5FU radiosensitization + chemotherapy
  - Chemotherapy
  - Supportive care
- Distant metastasis
  - Palliative care

Question

- If a lung cancer patient received xrt with 5FU as a radiosensitizer, is the 5FU coded as a single drug?
Answer

• Please check with SEER Rx and the physician. Generally, you do not code radiosensitizers.
• The low dose of the drug only enhances the effect of the radiation and does not kill cancer cells by itself.

Curator
(I & R Team)
24087

Gastric Cancer Surgery

• Resectable tumors
  — Endoscopic mucosal resection
  — Gastrectomy (distal, subtotal, or total) with regional lymph node dissection (15 or more nodes)
• Unresectable tumors
  — Gastric bypass with gastrojejunostomy to proximal stomach

Systemic therapy for gastric cancer

• Epirubicin, cisplatin, 5-FU
• Cicetaxel or paclitaxel plus fluoropyrimidine
• Cisplatin plus fluoropyrimidine
• Docetaxel, cisplatin, 5-FU
• Irinotecan plus cisplatin
• Trastuzumab
Radiation therapy

- External beam
  - Recommended dose range of 45-50.4 Gy in fractions of 1.8 Gy per day
- Intensity modulated radiation therapy (IMRT)
  - Use remains investigational in stomach cancer

Questions?

Next Month...

- Using CINA Data in Cancer Surveillance Activities
  - July 8, 2010

...August Webinar

- Lip and Oral Cavity
  - August 5, 2010